-
Health todayObesity, diabetes and GLP-1 new
GLP-1 receptor agonists obtained direct-to-consumer and compounded use in a US survey
Among US adults using GLP-1 receptor agonists, 73.0% buying direct-to-consumer reported compounded products, against 12.9% using clinicians or pharmacies.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 contradicts
GLP-1 receptor agonist cancer benefits may reflect immortal time bias in study design
Simulated study designs with no true effect gave hazard ratios of 0.39 to 0.85, close to published GLP-1 cancer estimates.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Bariatric operations versus incretin-based therapy in over-65s with type 2 diabetes
In a nationwide cohort of 107,280 adults aged 65 or over with type 2 diabetes and a BMI of 35 or more, bariatric surgery was linked to 23.0% weight loss at 1 year, against 6.87% with incretin-based therapy.
Peer-reviewed -
Health todayCancer confirms
GLP-1 receptor agonists and cancer risk in an umbrella review of 38 meta-analyses
In 48 placebo-controlled trials with 94 245 participants, GLP-1RAs showed no significant rise in overall or site-specific cancer.
Peer-reviewed -
Tomorrow's worldChanging behaviour at scale new
GLP-1 medication uptake among people with obesity modelled to 2050 for deaths and land use
Modelled GLP-1 calorie reduction gives up to 6.6 million avoided deaths and 32 Mha more natural land in 2050.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
First-line SGLT2 inhibitors versus metformin and cardiorenal outcomes in type 2 diabetes
In 36,720 matched pairs, starting SGLT2 inhibitors over metformin was associated with lower risk of major cardiovascular events and death.
Peer-reviewed -
Data, models and systemsHealth systems and access new
Medicaid GLP-1 weight-management dispensing fell 85% after four states ended coverage
Weight-management GLP-1 prescriptions in four Medicaid programmes fell 85% in one quarter, with no rise in diabetes-labelled dispensing.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Tirzepatide reduced BMI by 18.5% over 72 weeks in adolescents with obesity
In 160 adolescents with obesity, weekly tirzepatide cut BMI by 18.5% over 72 weeks, against a 0.5% rise with placebo.
Peer-reviewed -
Data, models and systemsValue in health new
Real-time glucose monitoring modelled at £5,943 per quality-adjusted life-year
A lifetime model gave £5,943 per QALY for FreeStyle Libre real-time monitoring over finger-prick testing in type 2 diabetes.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Clinical obesity has higher mortality than preclinical obesity in three cohorts
Against adults without obesity or organ dysfunction, clinical obesity had a mortality hazard ratio of 1.69 and preclinical obesity 1.19.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
GLP-1 medication use in US adults in 2025, including compounded versions and dose changes
About one in 10 US adults reported past-year GLP-1 use, and 44% of users changed how they took it.
Agency -
Health todayObesity, diabetes and GLP-1 refines
Lower systolic target in type 2 diabetes did not cut dementia or mild cognitive impairment
A systolic target below 120 mm Hg did not reduce dementia or mild cognitive impairment in type 2 diabetes.
Peer-reviewed